{"filing":{"accession_number":"0001104659-26-074023","cik":"0001446847","ticker":"IRWD","company_name":"IRONWOOD PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"tm2617503d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465926074023/tm2617503d1_8k.htm"},"events":[{"id":11006,"run_id":9645,"accession_number":"0001104659-26-074023","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Ironwood repaid $200 million in aggregate principal of convertible senior notes at scheduled maturity using available cash on hand. While this is a routine debt maturity event, the materiality of the amount ($200M) and the use of cash reserves to fund repayment would affect a reasonable investor's assessment of the company's liquidity and capital allocation. The disclosure does not fit neatly into debt covenant breach (no violation occurred) or other more specific categories, making \"other_material\" the most appropriate classification.","company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7476,"accession_number":"0001104659-26-074023","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Ironwood repaid $200 million in aggregate principal of convertible senior notes at scheduled maturity using available cash on hand. While this is a routine debt maturity event, the materiality of the amount ($200M) and the use of cash reserves to fund repayment would affect a reasonable investor's assessment of the company's liquidity and capital allocation. The disclosure does not fit neatly into debt covenant breach (no violation occurred) or other more specific categories, making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:07.557332+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7476,"accession_number":"0001104659-26-074023","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Ironwood repaid $200 million in aggregate principal of convertible senior notes at scheduled maturity using available cash on hand. While this is a routine debt maturity event, the materiality of the amount ($200M) and the use of cash reserves to fund repayment would affect a reasonable investor's assessment of the company's liquidity and capital allocation. The disclosure does not fit neatly into debt covenant breach (no violation occurred) or other more specific categories, making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:07.557332+00:00","company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","filing_date":"2026-06-15"}]}